Bilateral Essure Perforation into the Abdominal Cavity

Abstract

The Essure implant is a Food and Drug Administration (FDA) - approved form of hysteroscopic sterilization. The  device has been available since 2002 with over half a million placed in the United States. The safety and efficacy profile has been demonstrated in the literature and supported by the FDA. Here, we present a rare case of bilateral perforation into the abdominal cavity with one device ultimately let in-situ. Although Bayer, the manufacturer of Essure, plans to stop sale of the product by December 31, 2018 for financial reasons, providers may continue to have questions and concerns from implants placed previously.